CA2833320C - Dibenzothiazepine derivatives and their use in the treatment of cns disorders - Google Patents

Dibenzothiazepine derivatives and their use in the treatment of cns disorders Download PDF

Info

Publication number
CA2833320C
CA2833320C CA2833320A CA2833320A CA2833320C CA 2833320 C CA2833320 C CA 2833320C CA 2833320 A CA2833320 A CA 2833320A CA 2833320 A CA2833320 A CA 2833320A CA 2833320 C CA2833320 C CA 2833320C
Authority
CA
Canada
Prior art keywords
compound
alkyl
independently represent
formula
alkenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2833320A
Other languages
English (en)
French (fr)
Other versions
CA2833320A1 (en
Inventor
David Cavalla
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Numedicus Ltd
Original Assignee
Numedicus Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Numedicus Ltd filed Critical Numedicus Ltd
Publication of CA2833320A1 publication Critical patent/CA2833320A1/en
Application granted granted Critical
Publication of CA2833320C publication Critical patent/CA2833320C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
    • C07D281/02—Seven-membered rings
    • C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
    • C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
    • C07D281/12—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with two six-membered rings
    • C07D281/14—[b, e]-condensed

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
CA2833320A 2011-04-18 2012-04-16 Dibenzothiazepine derivatives and their use in the treatment of cns disorders Active CA2833320C (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GBGB1106520.8A GB201106520D0 (en) 2011-04-18 2011-04-18 Pharmaceutical compounds
GB1106520.8 2011-04-18
GB1113163.8 2011-08-01
GBGB1113163.8A GB201113163D0 (en) 2011-04-18 2011-08-01 Pharmaceutical compounds
PCT/GB2012/050831 WO2012143703A1 (en) 2011-04-18 2012-04-16 Dibenzothiazepine derivatives and their use in the treatment of cns disorders

Publications (2)

Publication Number Publication Date
CA2833320A1 CA2833320A1 (en) 2012-10-26
CA2833320C true CA2833320C (en) 2019-05-21

Family

ID=44147160

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2833320A Active CA2833320C (en) 2011-04-18 2012-04-16 Dibenzothiazepine derivatives and their use in the treatment of cns disorders

Country Status (9)

Country Link
US (1) US9487492B2 (https=)
EP (1) EP2699559B1 (https=)
JP (1) JP6030120B2 (https=)
CN (1) CN103717583B (https=)
CA (1) CA2833320C (https=)
DK (1) DK2699559T3 (https=)
ES (1) ES2574277T3 (https=)
GB (2) GB201106520D0 (https=)
WO (1) WO2012143703A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6557674B2 (ja) * 2014-03-12 2019-08-07 ザ・トラスティーズ・オブ・コランビア・ユニバーシティー・イン・ザ・シティー・オブ・ニューヨーク 新規クラスのミュー−オピオイド受容体アゴニスト
CA2998868A1 (en) 2015-09-16 2017-03-23 The Trustees Of Columbia University In The City Of New York Carboxylic diarylthiazepineamines as mu-opioid receptor agonists
GB201517133D0 (en) * 2015-09-28 2015-11-11 Numedicus Ltd New pharmaceutical use
WO2021222353A1 (en) 2020-04-30 2021-11-04 Gilead Sciences, Inc. Macrocyclic inhibitors of peptidylarginine deiminases
US20230365519A1 (en) * 2020-10-06 2023-11-16 Kures, Inc. Carboxylic diarylthiazepineamines and uses thereof
US20240092802A1 (en) * 2020-10-06 2024-03-21 Kures, Inc. Mu-opioid receptor agonists and uses therefor
CN118598743A (zh) * 2024-05-29 2024-09-06 康龙化成手性医药技术(宁波)有限公司 一种2,2-二甲基环丁烷甲酸的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1269551A (en) 1969-03-27 1972-04-06 Science Union & Cie New tricyclic derivatives and process for their manufacture
US3872102A (en) * 1971-11-04 1975-03-18 En Nom Collectif Science Union Tricyclic compounds of aliphatic w-amino alcohols
KR100604690B1 (ko) * 1999-07-09 2006-07-25 우베 고산 가부시키가이샤 디벤조티아제핀 유도체의 제조방법
CN1913900B (zh) * 2003-12-22 2010-11-24 阿卡蒂亚药品公司 作为毒蕈碱激动剂的氨基取代的二芳基[a，d]环庚烯类似物及神经精神疾病的治疗方法
US20050227961A1 (en) * 2004-04-08 2005-10-13 Vela Pharmaceuticals, Inc. Compositions and methods for treatment of neuropathic pain, fibromyalgia and chronic fatigue syndrome
CN101351210A (zh) * 2005-01-07 2009-01-21 阿斯利康公司 11－哌嗪－1－基二苯并[b,f][l,4]硫氮杂卓或其药学上可接受的盐的新用途及其用于口服药物组合物的新用途
EP1752143A1 (en) * 2005-08-08 2007-02-14 NewThera Novel uses for drugs targeting glutamine synthetase
JP5219465B2 (ja) * 2006-11-10 2013-06-26 大塚製薬株式会社 医薬
US9314469B2 (en) * 2008-05-05 2016-04-19 Tonix Pharma Holdings Limited Method for treating neurocognitive dysfunction
WO2010070667A2 (en) * 2008-11-19 2010-06-24 Biophore India Pharmaceuticals Pvt. Ltd. Novel process for the preparation of 7-((3-chloro-6-methyl-5,5-dioxo-6,11-dihydrodibenzo(c,f)(1,2) thiazepin-11-yl)amino)heptanoate

Also Published As

Publication number Publication date
US9487492B2 (en) 2016-11-08
CA2833320A1 (en) 2012-10-26
CN103717583B (zh) 2016-02-10
JP6030120B2 (ja) 2016-11-24
GB201113163D0 (en) 2011-09-14
CN103717583A (zh) 2014-04-09
DK2699559T3 (en) 2016-07-04
JP2014511897A (ja) 2014-05-19
US20140243317A1 (en) 2014-08-28
WO2012143703A1 (en) 2012-10-26
EP2699559A1 (en) 2014-02-26
EP2699559B1 (en) 2016-04-06
GB201106520D0 (en) 2011-06-01
ES2574277T3 (es) 2016-06-16

Similar Documents

Publication Publication Date Title
CA2833320C (en) Dibenzothiazepine derivatives and their use in the treatment of cns disorders
TWI306402B (en) N-[phenyl(piperidin-2-yl)methyl]benzamide derivatives, their preparation and their application in therapy
CN115974757A (zh) 用于治疗cns病症的作为血清素能致幻剂的赛洛辛衍生物
RU2351588C2 (ru) Производные n-фенил(пиперидин-2-ил)метил-бензамида и их применение в терапии
TW577887B (en) Polymorphic form I of a tachykinin receptor antagonist
JPH10506399A (ja) １−アシル−４−マリファチルアミノピペリジン化合物
CN111936139B (zh) 6-氨基异喹啉的单(酸)盐及其用途
CN101248069A (zh) 雄激素受体调节剂及用其治疗疾病的方法
AU2014231722B2 (en) Salts, co-crystals, and polymorphs of an anxiolytic compound
WO2013000399A1 (zh) 一种取代桂皮酰胺衍生物、制备方法及其应用
CN102070631B (zh) 戊乙奎醚光学异构体的季铵盐、药物组合物及其医药用途
JP2007297283A (ja) 新規桂皮酸関連化合物
CN103360342B (zh) 3-氰基苯胺烷基芳基哌嗪衍生物及在制备药物中的应用
US20230159439A1 (en) Arylamides and methods of use thereof
MXPA06011320A (es) Metodo de sintesis y aislamiento de n-desmetilclozapina solida y sus formas cristalinas.
TW200817322A (en) Compounds having activity at the GlyT1 transporter
WO2014063587A1 (zh) 一类氟取代的环状胺类化合物及其制备方法、药物组合物和用途
CN101712658A (zh) 1-丁基-2-羟基芳烷哌嗪衍生物及作为抗抑郁剂应用
CN102532114B (zh) 烟酸衍生物,其制备方法及其药物组合物
US20260035334A1 (en) Method of synthesis
JP2022515156A (ja) ボリナンセリンの重水素化形態および誘導体
US20090124630A1 (en) 3, 4-dihydro-2-naphthamide derivatives as selective dopamine d3 ligands
HK40106138A (zh) 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物
HK40105243A (zh) 作为血清素能药物的用於治疗与之相关的疾病的吲哚衍生物
HK40122714A (zh) 作为血清素能剂用於治疗相关障碍的吲哚啉衍生物

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20170126

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 13TH ANNIV.) - STANDARD

Year of fee payment: 13

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250224

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20250224

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250224

R11 Change to the name of applicant or owner or transfer of ownership requested

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R11-R127 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER RECORDAL REQUEST OR RESPONSE

Effective date: 20260211

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260213

R14 Transfer of ownership recorded

Free format text: ST27 STATUS EVENT CODE: A-4-4-R10-R14-R129 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: TRANSFER REQUIREMENTS DETERMINED COMPLIANT

Effective date: 20260219

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 14TH ANNIV.) - STANDARD

Year of fee payment: 14

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20260311

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20260312

W00 Other event occurred

Free format text: ST27 STATUS EVENT CODE: A-4-4-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT

Effective date: 20260413